Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $146,000, up from $50,000 in Q1 2025.

Cost of Revenue: $194,000, leading to a gross loss of approximately $48,000 (compared to a gross profit of $29,000 in the prior year).

Total Operating Expenses: $9.2 million, up from $8.6 million year-over-year, primarily due to increased R&D spending ($5.9 million vs. $4.9 million).

Net Loss: $9.1 million or $4.06 per share, compared to a net loss of $7.5 million or $7.05 per share in Q1 2025.

Adjusted EBITDA: Loss of $8.7 million, compared to a loss of $7.4 million in the prior year.

Cash and Cash Equivalents: $8.2 million at the end of Q1 2026, down from $11.9 million at the end of 2025.

2Strategic Updates and Business Highlights

Clinical Pipeline: Enrollment completed for the upper respiratory multiplex test with over 1,400 patients. An initial FDA submission is planned for Q3 2026, focusing on Flu A, Flu B, and RSV.

India Strategy: CoSara joint venture has received CDSCO clearance for 15 PCR tests and is set to manufacture the PCR Pro instrument locally, expanding its addressable market to approximately $13 billion.

Saudi Arabia Expansion: CoMira joint venture is progressing with local manufacturing plans, having secured industrial land allocation. This aligns with Saudi Arabia's Vision 2030 initiative.

Technological Advancements: Enhancements in connectivity, automation, and AI capabilities are being integrated into the platform to improve operational efficiency.

3Forward Guidance and Outlook

The company anticipates filing for FDA clearance in Q3 2026 and expects to commence TB testing commercialization in India by the end of Q3 2026.

Continued focus on disciplined capital allocation and potential financing alternatives, including equity and strategic partnerships, to support growth and development plans.

4Bad News, Challenges, or Points of Concern

Operating Losses: The company continues to experience significant operating losses, which are expected to persist in the near term.

Revenue Generation: Current revenue levels remain limited, and cost variability impacts gross margins.

Regulatory Risks: Dependence on successful regulatory submissions for product commercialization poses a risk.

Market Competition: The competitive landscape in molecular diagnostics, particularly in emerging markets like India, could pose challenges.

5Notable Q&A Insights

Scalability: The company is well-positioned to meet initial commercial demand, with plans for local manufacturing in India and Saudi Arabia to enhance efficiency and reduce costs.

Market Strategy: Emphasis on local manufacturing aims to improve accessibility and affordability of diagnostics in underserved regions, particularly in India.

Clinical Trials: The upcoming TB clinical trials will be conducted in larger medical centers, with a strategy to bridge the gap to smaller facilities post-clearance. Overall, Co-Diagnostics is making significant strides in its clinical and commercialization efforts, particularly in India and Saudi Arabia, while facing ongoing financial challenges and regulatory hurdles.